I degarelix 240/ 80 mg behandlingsgruppen afbrød 41 (20%) patienter forsøget, sammenlignet med 32 (16%) patienter i leuprorelin gruppen.
In the degarelix 240/ 80 mg treatment group 41 (20%) patients discontinued the study, as compared to 32 (16%) patients in the leuprorelin group.